U.S. markets closed
  • S&P Futures

    3,838.50
    -9.75 (-0.25%)
     
  • Dow Futures

    30,944.00
    -69.00 (-0.22%)
     
  • Nasdaq Futures

    11,858.25
    -22.00 (-0.19%)
     
  • Russell 2000 Futures

    1,724.50
    -4.10 (-0.24%)
     
  • Crude Oil

    97.21
    -1.32 (-1.34%)
     
  • Gold

    1,737.80
    +1.30 (+0.07%)
     
  • Silver

    19.09
    -0.06 (-0.33%)
     
  • EUR/USD

    1.0185
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • Vix

    26.73
    -0.81 (-2.94%)
     
  • GBP/USD

    1.1921
    -0.0001 (-0.00%)
     
  • USD/JPY

    135.6330
    -0.2820 (-0.21%)
     
  • BTC-USD

    20,507.17
    +325.67 (+1.61%)
     
  • CMC Crypto 200

    446.43
    +10.91 (+2.50%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,172.37
    +64.72 (+0.25%)
     

Amgen's Tezspire Reduces Annualized Exacerbation Rate In Severe Asthma Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Amgen Inc (NASDAQ: AMGN) shared results from a pooled post-hoc analysis of the NAVIGATOR Phase 3 and PATHWAY Phase 2b trials of Tezspire (tezepelumab-ekko) in broad asthma patient population.

  • Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

  • In the pooled analysis, Tezspire, when added to standard of care (SoC), reduced asthma exacerbations in patients, irrespective of baseline blood eosinophil counts, demonstrating consistent efficacy with a 71%, 48%, and 48% over 52 weeks, compared to placebo added to SoC.

  • Also See: Amgen Posts Latest Batch of Lumakras Data In Pancreatic Cancer.

  • In the same analysis, Tezspire also demonstrated improvements in AAER in patients regardless of fractional exhaled nitric oxide (FeNO) level and allergy status over 52 weeks, compared to placebo.

  • In a pre-specified exploratory analysis from NAVIGATOR, Tezspire showed consistent efficacy throughout the year regardless of the season.

  • The proportion of patients with an exacerbation was lower in the Tezspire group than in the placebo group across all seasons.

  • Price Action: AMGN shares closed 3.54% higher at $227.03 on Friday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.